Dong Kuang

Dong Kuang

Auto-generated profile, based on publicly available information

Dong Kuang

Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2019 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
NLNa Liu
Na Liu
JLJing Luo
Jing Luo
DKDong Kuang
Dong Kuang
SXSanpeng Xu
Sanpeng Xu
YDYaqi Duan
Yaqi Duan
XYXiang-Ping Yang
Xiang-Ping Yang
Macrophages perform key functions in tissue homeostasis that are influenced by the local tissue environment. Within the tumor microenvironment tumor associated macrophages can be altered to acquire properties that enhance tumor growth. Here, we found lactate, a metabolite found in high concentration within the anaerobic tumor environment, activated mTORC1 that subsequently suppressed TFEB-mediated expression of a macrophage-specific vacuolar ATPase subunit ATP6V0d2. Atp6v0d2-/- mice were more susceptible to tumor growth with enhanced HIF-2α-mediated VEGF production in macrophages that display a more protumoral phenotype. We found that ATP6V0d2 targeted HIF-2α but not HIF-1α for lysosome-mediated degradation. Blockade of HIF-2α transcriptional activity reversed the susceptibility of Atp6v0d2-/- mice to tumor development. Furthermore, in a cohort of patients with lung adenocarcinoma, expression of ATP6V0d2 and HIF-2α was positively and negatively correlated with survival respectively, suggesting a critical role of the macrophage lactate-ATP6V0d2-HIF-2α axis in maintaining tumor growth in human patients. Together, our results highlight the ability of tumor cells to modify the function of tumor-infiltrating macrophages to optimize the microenvironment for tumor growth.

1 June 2020 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
YCYixin Cai
Yixin Cai
ZHZhipeng Hao
Zhipeng Hao
YGYi Gao
Yi Gao
WPWei Ping
Wei Ping
QWQi Wang
Qi Wang
NZNi Zhang
Ni Zhang

1 July 2019 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
ZTZhen Tao
Zhen Tao
HRHailong Ruan
Hailong Ruan
LSLin Sun
Lin Sun
DKDong Kuang
Dong Kuang
YSYongchun Song
Yongchun Song
KCKe Chen
Ke Chen
Tumor cells can escape immune destruction in tumor chemoresistance, but the mechanism for this phenomenon remains unclear. Y-box binding protein 1 (YB-1), which is upregulated in chemoresistant tumor cells, plays a role in the acquisition of multidrug resistance. Here, we demonstrate that chemotherapy induced an immunosuppressive microenvironment in the tumor and induced immune evasion through YB-1–mediated programmed death-1 ligand 1 (PD-L1) upregulation. Examination of the YB-1 protein and mRNA showed an increase in YB-1 expression in hepatocellular carcinoma (HCC). High YB-1 expression negatively correlated with the overall survival of HCC patients. YB-1 expression positively correlated with PD-L1, and YB-1 induced PD-L1 expression by binding a PD-L1 promoter motif. YB-1 expression was upregulated in chemoresistant HCC cells, and YB-1 knockdown reversed chemoresistance via T-cell activation in the tumor microenvironment due to blocked PD-L1 expression. We also found that inhibition of the tumor immunosuppressive environment and immune evasion was accompanied by proliferation of functional cytotoxic CD8+ T cells and inhibition of myeloid-derived suppressor cells and regulatory T cells in the tumor environment. Our data indicate that targeting the YB-1 signaling axis, which simultaneously reverses both tumor immune evasion and multidrug resistance, may improve the antitumor response. This finding suggests a treatment modality against tumor chemoresistance.

17 December 2007 in Basic Research in Cardiology
Verified
Journal Article
Closed access
PDF file
DKDong Kuang
Dong Kuang
XZXia Zhao
Xia Zhao
GXGuixiang Xiao
Guixiang Xiao
JNJuan Ni
Juan Ni
YFYoumei Feng
Youmei Feng
GWGuoping Wang
Guoping Wang

18 November 2015 in Scientific Reports
Verified
Journal Article
Open access
DCDong Chen
Dong Chen
YXYanli Xia
Yanli Xia
KZKe Zuo
Ke Zuo
YWYing Wang
Ying Wang
SZShiying Zhang
Shiying Zhang
GWGuoping Wang
Guoping Wang
Stromal cell-derived factor 1 (SDF-1) is a chemokine that can be expressed in injured cardiomyocytes after myocardial infarction (MI). By combining with its receptor CXCR4, SDF-1 induced stem and progenitor cells migration. CXCR7, a novel receptor for SDF-1, has been identified recently. We aimed to explore the roles of SDF-1/CXCR4 and SDF-1/CXCR7 pathway and their crosstalk in CSCs migration. In the present study, CXCR4 and CXCR7 expression were identified in CSCs. Transwell assay showed that SDF-1 caused CSCs migration in a dose- and time-dependent manner, which could be significantly suppressed by CXCR4 or CXCR7 siRNA. Phospho-ERK, phospho-Akt and Raf-1 significantly elevated in CSCs with SDF-1 stimulation. Knockdown of CXCR4 or CXCR7 significantly decreased phospho-ERK or phospho-Akt, respectively and eventually resulted in the inhibition of CSCs migration. Moreover, western blot showed that MK2206 (Akt inhibitor) increased the expression of phospho-ERK and Raf-1, whereas PD98059 (ERK inhibitor) had no effect on phospho-Akt and Raf-1. GW5074 (Raf-1 inhibitor) upregulated the expression of phospho-ERK, but had no effect on phospho-Akt. The present study indicated that SDF-1/CXCR7/Akt and SDF-1/CXCR4/ERK pathway played important roles in CSCs migration. Akt phosphorylation inhibited Raf-1 activity, which in turn dephosphorylated ERK and negatively regulated CSCs migration.

12 August 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
YCYaobing Chen
Yaobing Chen
DKDong Kuang
Dong Kuang
XZXia Zhao
Xia Zhao
DCDong Chen
Dong Chen
XWXiaoyan Wang
Xiaoyan Wang
YDYaqi Duan
Yaqi Duan
MiR-497-5p inhibits cell proliferation and invasion by targeting KCa3.1 in angiosarcoma miR-497-5p inhibits cell proliferation and invasion by targeting KCa3.1 in angiosarcoma